(Q31129877)

29 June 2017

1 reference

title

Quality assessment of digital annotated ECG data from clinical trials by the FDA ECG Warehouse (English)

1 reference

29 June 2017

Nenad Sarapa

1

1 reference

29 June 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Drug Safety

29 June 2017

published in

1 reference

29 June 2017

volume

6

1 reference

29 June 2017

issue

5

1 reference

29 June 2017

page(s)

595-607

1 reference

Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms

29 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

Drug-induced torsades de pointes and implications for drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

Clinical utility of the Food and Drug Administration Electrocardiogram Warehouse: a paradigm for the critical pathway initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

New era for digital ECG: FDA requires digital ECG submission for tested drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

Annotated ECG waveform data at FDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

Errors in manual measurement of QT intervals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

Assessment of noise in digital electrocardiograms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

Errors and misconceptions in ECG measurement used for the detection of drug induced QT interval prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

Implications of methodological differences in digital electrocardiogram interval measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

Man versus machine: is there an optimal method for QT measurements in thorough QT studies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

Precision of QT interval measurement by advanced electrocardiographic equipment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.5.595

21 January 2018

Identifiers

DOI

10.1517/14740338.6.5.595

1 reference

29 June 2017

1 reference